



1·2·3 FÉVRIER 2023

MARSEILLE·PALAIS DU PHARO



Prévenir l'occlusion coronaire: nouvelle technique!


Dr Vincent BALMETTE

Mme L. 87 ans:

-dégénérescence
bioprothèse suturale

Perceva

-ATCDS
FA; PM




Contexte Clinique/indication :

Valve Size Selection	Evolut R and PRO TAVs			Evolut R TAV
Size	23 mm	26 mm	29 mm	34 mm
Annulus Diameter	17*/18-20 mm	20-23 mm	23-26 mm	26-30 mm
Annulus Perimeter ($\pi \times$ Diameter)	53.4*/56.5-62.8 mm	62.8-72.3 mm	72.3-81.7 mm	81.7-94.2 mm
Sinus of Valsalva Diameter (Mean)	≥ 25 mm	≥ 27 mm	≥ 29 mm	≥ 31 mm
Sinus of Valsalva Height (Mean)		≥ 15 mm		≥ 16 mm

- **Evolut pro+ 29 mm**

Size: M THV Selector: Current



Acurate NEO S	Allegra 23
Evolut 26	Portico 23/25
S3 23	

ID Type	Label	Value
1	Polygon Min. \emptyset	21,0 mm
	Max. \emptyset	26,6 mm
	Avg. \emptyset	23,8 mm
	Area derived \emptyset	23,1 mm
	Perimeter derived \emptyset	23,7 mm
	Area	418,2 mm ²
	Perimeter	74,4 mm

VTC < 4 mm




Ribeiro HB et al, Eur Heart J 2018

Table 3 Computed tomography data, according to the occurrence of coronary obstruction following transcatheter aortic valve replacement

	Controls (n = 90)	Coronary obstruction (n = 20)	P-value
Surgical frame mean diameter (mm)	20.6 ± 2.6	21.1 ± 3.3	0.39
Surgical frame area (cm ²)	3.37 ± 0.85	3.59 ± 1.25	0.35
SOV width (mm)	32.55 ± 3.98	27.44 ± 4.05	<0.001
STJ height (mm)	19.25 ± 3.97	20.01 ± 7.58	0.52
LCA height to annulus distance (mm)	9.69 ± 4.12	9.48 ± 2.67	0.82
RCA height to annulus distance (mm)	11.17 ± 4.33	11.97 ± 2.52	0.43
LCA originates above the posts	5/86 (5.8)	0 (0)	0.27
RCA originate above the posts	14/86 (16.3)	0 (0)	0.05
VTC to LCA (mm)	6.30 ± 2.34	3.24 ± 2.22	<0.001
VTC to RCA (mm)	6.08 ± 2.43	3.90 ± 3.49	0.002

Procédure:



BASILICA®

cheminée





Autre technique ?





Pi-Cardia

Next-Generation Valve Repair


Procédure:




Procédure:





LC isolation





Procédure



Procédure:



Procédure:




Take Home Messages:

- TAVI ViV + fréquent (vieillesse population, + bioprothèses valvulaires, extension indication TAVI)
- Obstruction coronaire: 3,5% (TAVI ViV)
>50% mortalité J30
- **Shortcut** = alternative séduisante dans la boîte à outils du cardio. Interv. (cheminée, BASILICA)



Ribeiro HB et al, J Am Coll Cardiol. 2013

Merci de votre attention



Splitting element activated

ShortCut™ Catheter Handle

SHORTCUT
PROCEDURAL
STEPS TD-
REC-002_REV
02

